Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) said management will attend two institutional investor conferences in March 2026: TD Cowen (March 2-4) and Barclays Global Healthcare (March 10-12). Fireside chats are scheduled for March 3 at 9:50am ET and March 11 at 8:00am ET, with webcasts available live and archived on the company’s investor relations site.
Positive
- None.
Negative
- None.
News Market Reaction – OBIO
On the day this news was published, OBIO declined 0.50%, reflecting a mild negative market reaction. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $225M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed single-day moves: CYBN +0.12%, THTX +0.89%, GLSI -3.05%, SGMO -2.00%, PLX 0.00%, suggesting stock-specific factors rather than a unified sector move around this conference update.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 13 | Inducement grants | Neutral | +0.3% | Stock options for 120,000 shares granted to nine new employees. |
| Jan 12 | Vivasure proceeds | Positive | -2.9% | Company expects up to $21M cash from Vivasure sale to Haemonetics. |
| Jan 09 | Vivasure acquisition | Neutral | -0.8% | Vivasure acquired by Haemonetics in a milestone-based transaction. |
| Dec 08 | Conference presentations | Neutral | -0.2% | Multiple ICI meeting talks on AVIM Therapy and Virtue SAB program. |
| Nov 26 | Inducement grants | Neutral | +1.5% | Stock options for 151,250 shares granted to 12 new employees. |
Recent news has been operational (inducement grants, conference presentations) and strategic (Vivasure proceeds), with generally modest price reactions and one notable divergence on positive cash-proceeds news.
Over the past several months, Orchestra BioMed reported multiple corporate and strategic updates. Inducement option grants on Nov 24, 2025 and Feb 12, 2026 led to small positive moves of 1.53% and 0.26%. The Vivasure acquisition by Haemonetics and related expectation of up to $21 million in proceeds produced modest negative reactions of -0.83% and -2.92%. The December 2025 ICI meeting presentations on AVIM Therapy and Virtue SAB were followed by a slight -0.23% move. Today’s conference participation fits this pattern of mainly informational, visibility-oriented announcements.
Regulatory & Risk Context
An effective S-3 shelf filed on Oct 31, 2025 registers up to 8,027,890 resale shares held by existing stockholders. The company does not receive proceeds from these resales but may receive up to $7.3 million if the Ligand warrant is exercised for cash at an exercise price of $3.67 per share.
Market Pulse Summary
This announcement highlights Orchestra BioMed’s upcoming participation in major healthcare investor conferences, providing platforms for management to share updates through fireside chats and one-on-one meetings. In recent months, the company has reported strategic developments, including potential proceeds of up to $21 million from the Vivasure transaction and multiple scientific presentations on AVIM Therapy and Virtue SAB. Investors may watch for any new disclosures or partnership details emerging from these events and how they relate to prior milestones.
AI-generated analysis. Not financial advice.
NEW HOPE, Pa., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced that company management will participate in multiple upcoming institutional investor conferences. Details on the Company’s participation appear below:
TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 (Boston, MA)
Management will participate in a live fireside chat at 9:50am ET on Tuesday, March 3rd and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
Barclays 28th Annual Global Healthcare Conference – March 10-12, 2026 (Miami, FL)
Management will participate in a live fireside chat at 8:00am ET on Wednesday, March 11th and will also host one-on-one meetings with investors. The event will be accessible to investors and interested parties via a live webcast, which will be available live via this link, as well as after the event on Orchestra BioMed’s Investor Relations website.
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
kkirkellis@orchestrabiomed.com
FAQ
When will Orchestra BioMed (OBIO) present at the TD Cowen 46th Annual Health Care Conference?
What time is Orchestra BioMed's (OBIO) fireside chat at the Barclays 28th Annual Global Healthcare Conference?
How can investors watch Orchestra BioMed (OBIO) presentations from the March 2026 conferences?
Will Orchestra BioMed (OBIO) hold investor meetings at the March 2026 conferences?
Which conferences will Orchestra BioMed (OBIO) attend in March 2026 and where are they located?
Will Orchestra BioMed's (OBIO) March 2026 conference presentations be available after the events?
